This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
27 Oct 2020

Alfasigma increases prefilled syringes and vials capacity in its sterile department at Alanno plant

Italian pharma company Alfasigma has increased its capacity for the production of pre-filled syringes in its sterile department of excellence at its Alanno manufacturing plant.

The sterile department is wholly dedicated to the production of pre-filled syringes, cartridges, and ready-to-use vials, and is equipped with a high-performance, versatile filling line with an output of 36,000 pcs/h.

This high-quality manufacturing performance includes the option to use either peristaltic or volumetric pumps, the ability to manage oxygen-sensitive products, and accuracy in the plunger stopper placement and has 100% in-process control (IPC).

Fully integrated sterilization systems (ovens, autoclaves, passboxes) ensure the safety of the aseptic area in the line, according to top-quality standard requirements.

All equipment is connected to a validated computer system in order to guarantee the complete traceability and integrity of the data.

Given its advanced technical characteristics, this line is particularly suitable for supporting production processes requiring outstanding reliability for the manufacturing of high-value products such as biotechnology compounds, biosimilars, and vaccines.

The expansion has increased Alfasigma’s overall annual production capacity to 150 million pre-filled syringes, which is welcome news given the increased demand related to the current COVID-19 pandemic situation.

Alfasigma is a privately owned, Italy-based integrated multinational pharmaceutical company with revenues in excess of €1 billion, five manufacturing plants, R&D facilities, and 3,000 employees globally. Outside of its core Italian market, Alfasigma has 16 subsidiaries in Europe, Asia, North and Central America, and Africa, and is present in more than 90 countries.

The Alanno plant processes rifaximin, a molecule for the treatment of gastrointestinal disorders, which holds the record for US sales of an Italian-owned drug (over €1.5 billion euros, according to IQVIA).
Click here to download an infographic on Alfasigma's two sterile departments at Alanno.
Click here to download an infographic on Alfasigma's products and services.

Mentioned Companies
Alfasigma
View company profile

Related News